DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Is Carotid Body Infection Responsible for Silent Hypoxemia in COVID-19 Patients?
The pathogenic mechanisms underlying the symptomatology
of coronavirus disease 2019 (COVID-19) patients are not well understood. An atypical and bewildering clinical manifestation
found in many COVID-19 patients is that they exhibit severe
hypoxemia, with arterial levels of oxygen (O2) tension even below 50 mmHg, without clear signs of distress (dyspnea) or significant acceleration of breathing.1,2 Under these conditions,
patients with COVID-19 pneumonia may decompensate and as
a consequence undergo a rapid deterioration of their clinical
state that can eventually lead to death. The pathophysiology of
this so-called “silent hypoxemia”3 or “happy hypoxia” is unknown.1,3,4 A decline in arterial O2 tension is normally detected
by O2-sensing cells in the carotid body (CB), the main arterial
chemoreceptor, which rapidly activates sensory fibers impinging on neurons in the brainstem to induce compensatory hyperventilation and increased heart rate. In this way, both O2 uptake
and its distribution to the tissues are enhanced. Bilateral removal of the CB in humans leaves individuals unaware of hypoxemia, with complete abolition of the hypoxic ventilatory
response.5 Therefore, inhibition of CB responsiveness to hypoxia could be a plausible explanation for the impaired respiratory drive and reduced dyspnea that characterizes the “silent
hypoxemia” observed in COVID-19 patients, Experimental work in the authors’ laboratories is supported
by the Spanish Ministries of Science and Health (grants
PID2019-106410RBI00, PID2019-105995RB-I00, and Red
Tema´tica de Investigacio´n Cooperativa “Terapia Celular”
RD16/0011/0025) and the European Research Council (ERC
Advanced Grant PRJ201502629), Peer reviewed